Ovid Therapeutics (OVID) Gains from Investment Securities (2016 - 2023)
Ovid Therapeutics (OVID) reported Gains from Investment Securities of $12000.0 for Q4 2023, down 99.92% on a YoY basis from $15.8 million in Q4 2022, and up 200.0% quarter-over-quarter from -$12000.0 in Q1 2023.
Ovid Therapeutics (OVID) Gains from Investment Securities (2016 - 2023) Analysis & Trends
Ovid Therapeutics has reported Gains from Investment Securities for 8 years, with the latest figure at $12000.0 in Q4 2023.
- For the quarter ending Q4 2023, Gains from Investment Securities fell 99.92% year-over-year to $12000.0; the trailing twelve-month figure through Sep 2024 stood at $12000.0 (down 99.92% YoY), and the FY2022 full-year result was $15.8 million, up 46.54% from the prior year.
- Gains from Investment Securities for Q4 2023 stood at $12000.0, up from -$12000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $15.8 million in Q4 2022, with the low at -$15.8 million in Q2 2022.
- Historically, Gains from Investment Securities has averaged $1.3 million across 5 years, with a median of $11000.0 in 2020.
- Annual changes were most pronounced in 2021 — Gains from Investment Securities soared 109548.89% — and 2022, when it sank 244.06%.
- Ovid Therapeutics' Gains from Investment Securities stood at $7.4 million in 2019, then slumped by 106.6% to -$488384.0 in 2020, then jumped by 310.17% to $1.0 million in 2021, then jumped by 1444.08% to $15.8 million in 2022, then sank by 99.92% to $12000.0 in 2023.
- The last three Gains from Investment Securities figures came in at $12000.0 (Q4 2023), -$12000.0 (Q1 2023), and $15.8 million (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ovid Therapeutics | 311.83 Mn | 156.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 12,000.00 |
| Dec 31, 2023 | 12,000.00 |
| Mar 31, 2023 | -12,000.00 |
| Mar 31, 2023 | -12,000.00 |
| Dec 31, 2022 | 15.85 Mn |
| Dec 31, 2022 | 15.85 Mn |
| Sep 30, 2022 | -41,023.00 |
| Sep 30, 2022 | -41,023.00 |
| Jun 30, 2022 | -15.80 Mn |
| Jun 30, 2022 | -15.80 Mn |
| Mar 31, 2022 | 434,101.00 |
| Mar 31, 2022 | 434,101.00 |
| Sep 30, 2021 | 1.03 Mn |
| Sep 30, 2021 | 1.03 Mn |
| Jun 30, 2021 | 10.96 Mn |
| Jun 30, 2021 | 10.96 Mn |
| Mar 31, 2021 | 6,836.00 |
| Mar 31, 2021 | 6,836.00 |
| Dec 31, 2020 | -488,384.00 |
| Dec 31, 2020 | -488,384.00 |